FDA Approves AbbVie's RINVOQ Therapy For Active Non-Radiographic Axial Spondyloarthritis

By Kathryn Hardison

The Food and Drug Administration has approved AbbVie Inc.'s RINVOQ(R) drug for the treatment of adults with active non-radiographic axial spondyloarthritis.

The company said Friday that the oral therapy was approved for people with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.

This follows the FDA's approval of RINVOQ in April for adults with active ankylosing spondylitis, the company said.

RINVOQ is also used to treat adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and moderate to severe ulcerative colitis. The drug is also used to treat adults and children 12 years of age and older with moderate to severe eczema.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

October 21, 2022 17:15 ET (21:15 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024